Introduction: Over the last 3 years, the FDA has approved dupilumab, omalizumab, and mepolizumab for the treatment of CRSwNP; however, adverse events of these biologics have not been described in post-marketing surveillance trials. By utilizing the FDA Adverse Event Reporting System (FAERS), this study describes and compares biologic-associated adverse events in T2 disease. Methods: This case-non-case study assessed disproportionate reporting rates using reporting odds ratios (RORs). RORs and p values for biologic-associated AEs were categorized and compared among dupilumab, omalizumab, and mepolizumab. This analysis included AEs associated with all treatment indications. Relative AE rates and outcomes were calculated. Results: There were a total of 112,560, 24,428, and 18,741 unique AE reports associated with dupilumab, omalizumab, and mepolizumab, respectively. Omalizumab had the strongest association with anaphylaxis (ROR = 20.80, 95% confidence interval [CI]: 18.58, 23.29). Dupilumab had large relative proportions and positive signals in the ophthalmologic category (7.76%, ROR = 6.20, 95% CI: 6.06, 6.35), such as with blurry vision (ROR = 3.80, CI: 3.52, 4.12) and visual impairment (ROR = 1.98, CI: 1.80, 2.19). Dupilumab was the only biologic associated with injection-site reactions (7.98%, ROR = 8.17, 95% CI: 7.98, 8.37). Discussion/Conclusion: This is the first large-scale comparative analysis of the AE profiles of dupilumab, omalizumab, and mepolizumab. Our data suggest possible relations between dupilumab and ophthalmologic and injection-site AEs. Omalizumab was the only biologic with a positive anaphylaxis signal. This FAERS investigation suggests important AE differences among these biologics.

1.
U. S. F. a. D. Administration
. FDA approves first treatment for chronic rhinosinus- itis with nasal polyps. S. Silver spring: food and drug administration.
2019
.
2.
Bachert
C
,
Han
JK
,
Desrosiers
M
,
Hellings
PW
,
Amin
N
,
Lee
SE
.
Efficacy and safety of dupilumab in patients with severe chronic rhinosinusitis with nasal polyps (LIBERTY NP SINUS-24 and LIBERTY NP SINUS-52): results from two multicentre, randomised, double-blind, placebo-controlled, parallel-group phase 3 trials
.
Lancet
.
Nov 2 2019
394
10209
1638
50
.
3.
Damask
C
,
Chen
M
,
Holweg
CTJ
,
Yoo
B
,
Millette
LA
,
Franzese
C
.
Defining the efficacy of omalizumab in nasal polyposis: a POLYP 1 and POLYP 2 subgroup analysis
.
Am J Rhinol Allergy
.
Jan 2022
36
1
135
41
.in eng)
4.
Han
JK
,
Bachert
C
,
Fokkens
W
,
Desrosiers
M
,
Wagenmann
M
,
Lee
SE
.
Mepolizumab for chronic rhinosinusitis with nasal polyps (SYNAPSE): a randomised, double-blind, placebo-controlled, phase 3 trial
.
Lancet Respir Med
.
Oct 2021
9
10
1141
53
.in eng)
5.
Lee
DJ
,
Cramer
HB
,
Kshirsagar
RS
,
Douglas
JE
,
Kohanski
MA
,
Palmer
JN
.
Dupilumab-related adverse events among patients with chronic rhinosinusitis with nasal polyposis
.
Int Forum Allergy Rhinol
.
Aug 2023
13
8
1542
5
.
6.
Lyly
A
,
Genberg
E
,
Kauppi
P
,
Virkkula
P
,
Lee
SE
,
Laidlaw
TM
.
Real-life experience of biologic treatment for asthma on chronic rhinosinusitis: a finnish cohort
.
Int Arch Allergy Immunol
.
2023
;
184
(
2
):
149
160
.
7.
Swisher
AR
,
Kshirsagar
RS
,
Adappa
ND
,
Liang
J
.
Dupilumab adverse events in nasal polyp treatment: analysis of FDA adverse event reporting system
.
Laryngoscope
.
Dec 2022
132
12
2307
13
. (in eng).
8.
Bridgewood
C
,
Wittmann
M
,
Macleod
T
,
Watad
A
,
Newton
D
,
Bhan
K
.
T helper 2 IL-4/IL-13 dual blockade with dupilumab is linked to some emergent T helper 17‒type diseases, including seronegative arthritis and enthesitis/enthesopathy, but not to humoral autoimmune diseases
.
J Invest Dermatol
.
Oct 2022
142
10
2660
7
.
9.
Chromy
D
,
Bartosik
T
,
Brkic
FF
,
Quint
T
,
Tu
A
,
Eckl-Dorna
J
.
Dupilumab-induced skin-associated side effects in patients with chronic rhinosinusitis with nasal polyposis
.
J Dermatol
.
Jan 2023
50
1
89
93
.in eng)
10.
Trimarchi
M
,
Indelicato
P
,
Vinciguerra
A
,
Bussi
M
.
Clinical efficacy of dupilumab in the treatment of severe chronic rhinosinusitis: The first case outside of a clinical trial
.
Clin Case Rep
.
2021 Jan 16
9
3
1428
1432
.
11.
Domingo Ribas
C
,
Carrillo Díaz
T
,
Blanco Aparicio
M
,
Martínez Moragón
E
,
Banas Conejero
D
,
Sánchez Herrero
MG
.
REal worlD effectiveness and safety of mepolizumab in a multicentric Spanish cohort of asthma patients stratified by eosinophils: the REDES study
.
Drugs
.
Oct 2021
81
15
1763
74
. (in eng).
12.
Casas-Maldonado
F
,
Álvarez-Gutiérrez
FJ
,
Blanco-Aparicio
M
,
Domingo-Ribas
C
,
Cisneros-Serrano
C
,
Soto-Campos
G
.
Monoclonal antibody treatment for severe uncontrolled asthma in Spain: analytical map
.
J Asthma
.
2022 Oct
59
10
1997
2007
.
13.
Bian
S
,
Zhang
P
,
Li
L
,
Wang
Z
,
Cui
L
,
Xu
Y
.
Anaphylaxis associated with allergen specific immunotherapy, omalizumab, and dupilumab: a real world study based on the US food and drug administration adverse event reporting system
.
Front Pharmacol
.
2021
;
12
:
767999
.
14.
Li
L
,
Wang
Z
,
Cui
L
,
Xu
Y
,
Guan
K
,
Zhao
B
.
Anaphylactic risk related to omalizumab, benralizumab, reslizumab, mepolizumab, and dupilumab
.
Clin Transl Allergy
.
Jun 2021
11
4
e12038
.
15.
Cai
S
,
Xu
S
,
Lou
H
,
Zhang
L
.
Comparison of different biologics for treating chronic rhinosinusitis with nasal polyps: a network analysis
.
J Allergy Clin Immunol Pract
.
2022 Jul
10
7
1876
1886.e7
.
16.
Chong
LY
.
Biologics for chronic rhinosinusitis
.
Cochrane Database Syst Rev
.
2021 Mar 12
3
3
CD013513
.
17.
Wu
Q
,
Zhang
Y
,
Kong
W
,
Wang
X
,
Yuan
L
,
Zheng
R
.
Which is the best biologic for nasal polyps: dupilumab, omalizumab, or mepolizumab? A network meta-analysis
.
Int Arch Allergy Immunol
.
2022
;
183
(
3
):
279
288
.
18.
F. a. D. A. F. [Internet]
Drugs@FDA data files
. Available from: https://www.fda.gov/drugs/drug-approvals-and-databases/drugsfda-data-files. (accessed 2022).
19.
M. M. a. S. S. O. (MSSO)
Medical dictionary for regulatory Activities (MedDRA)
.
2022
. Available from: https://www.meddra.org. (accessed 2022).
20.
Chen
Y
,
Guo
JJ
,
Steinbuch
M
,
Lin
X
,
Buncher
CR
,
Patel
NC
.
Comparison of sensitivity and timing of early signal detection of four frequently used signal detection methods
.
Pharmaceut Med
.
2008
;
22
(
6
):
359
65
.
21.
Rothman
KJ
,
Lanes
S
,
Sacks
ST
.
The reporting odds ratio and its advantages over the proportional reporting ratio
.
Pharmacoepidemiol Drug Saf
.
2004 Aug
13
8
519
23
.
22.
Sakaeda
T
,
Tamon
A
,
Kadoyama
K
,
Okuno
Y
.
Data mining of the public version of the FDA adverse event reporting system
.
Int J Med Sci
.
2013
;
10
(
7
):
796
803
.
23.
Wisniewski
AF
,
Bate
A
,
Bousquet
C
,
Brueckner
A
,
Candore
G
,
Juhlin
K
.
Good signal detection practices: evidence from IMI PROTECT
.
Drug Saf
.
Jun 2016
39
6
469
90
.
24.
Caster
O
,
Aoki
Y
,
Gattepaille
LM
,
Grundmark
B
.
Disproportionality analysis for pharmacovigilance signal detection in small databases or subsets: recommendations for limiting false-positive associations
.
Drug Saf
.
2020
;
43
(
5
):
479
87
.
25.
Patel
GB
,
Peters
AT
.
The role of biologics in chronic rhinosinusitis with nasal polyps
.
Ear Nose Throat J
.
Jan 2021
100
1
44
7
.
26.
Fokkens
WJ
,
Lund
V
,
Bachert
C
,
Mullol
J
,
Bjermer
L
,
Bousquet
J
.
EUFOREA consensus on biologics for CRSwNP with or without asthma
.
Allergy
.
2019 Dec
74
12
2312
2319
.
You do not currently have access to this content.